AGFA HealthCare
MORTSEL, BELGIUM / ACCESSWIRE / June 10, 2024 / AGFA HealthCare is thrilled to announce a significant new deal with Alliance Medical to implement an advanced cloud-based solution across all of Alliance Medical's UK sites. Powered by the AGFA HealthCare Enterprise Imaging Platform, this state-of-the-art approach supports Alliance Medical UK's Future Unified Diagnostic Information System (FUDIS) project. This project aims to streamline the entire patient pathway, establishing a robust and lasting partnership between AGFA HealthCare and Alliance Medical.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Deployment of the solution will begin later in 2024, with a phased implementation approach to ensure a smooth and efficient transition of all imaging services across 120 sites for all of Alliance Medical's UK community diagnostic centres (CDCs), static imaging sites for PET-CT, MRI, CT and other imaging modalities and its extensive fleet of mobile, modular and relocatable units, delivering over 400,000 annual exams.
Efficiency gains, clinical effectiveness, and collaboration workflows
Alliance Medical has been a trusted partner to the NHS for 30 years, providing diagnostic imaging solutions to patients throughout the UK. This partnership with AGFA HealthCare will play a pivotal role in achieving the strategic vision for Alliance Medical's UK business to provide long-term, sustainable diagnostic imaging solutions on behalf of the NHS and other partners.
"The ground-breaking partnership between Alliance Medical and AGFA HealthCare will play a key role in enabling us to achieve our strategic vision, on behalf of our patients and stakeholders, and will support our commitment to integrating diagnostics into existing care pathways. AGFA HealthCare's solution really led from the front, and the digital ecosystem they brought together will deliver the experience, knowledge and innovation needed to create a complete cloud-based solution which covers the entire end-to-end patient pathway," says Pete Winchester, UK Managing Director at Alliance Medical.
"We are delighted to further strengthen our partnership with Alliance Medical Group and the relationship with Alliance Medical UK, which is an integral part of the health economy in the UK and beyond. Combining that bond with our close collaboration with our market-leading partners will enable us to jointly deliver a luminary solution that brings together each of our leading technologies: enterprise imaging, clinical decision support, complex workflow orchestration and advanced augmented intelligence. These will run through the heart of the solution to enable clinicians to deliver outcomes for patients and an exceptional user experience that is rich in efficiency gains," says Roberto Anello, Regional President for Northern Europe for AGFA HealthCare.
Transformative Technologies Delivering an Exceptional User Experience
- The solution includes the AGFA HealthCare Enterprise Imaging Platform, with Shared Workflow and the XERO® Exchange Network (XEN):
- Designed around scalability, connectivity and clinical collaboration, Enterprise Imaging enables near-real-time access to images and delivers powerful tools and features for diagnosis, collaboration, workflow and more. By facilitating "imaging without barriers," it supports patient and clinician work-life balance, as well as the balancing of radiologists' tasks and reporting workloads between different organisations.
- Fully embedded artificial intelligence and advanced visualisation tools for molecular imaging all support complex clinical workflows by providing a solution that is readily available regardless of location and time.
- The Enterprise Imaging Collaborator tool and the new Shared Workflow feature offer completely new ways of managing activity to match reporting capacity with demand, improve clinician collaboration through multi-author workflows, and align unified ‘specialist' Reporting Worklists with scarce reporting skills. The embedded XERO® application enables clinical teams to engage and share information. Enterprise Imaging is now entering the era of streaming clients capable of displaying large amounts of data in near real-time.
- AGFA HealthCare Enterprise Imaging is powered by Amazon Web Services (AWS) cloud services, which gives Alliance Medical access to the security, reliability and scalability of the public cloud.
The platform is complemented for referrals by two market-leading solutions, including:
- xWave Technologies' Smart Referring, an advanced portal for referring clinicians, integrated with Enterprise Imaging XERO®. xWave Smart Referring incorporates a dynamic Clinical Decision Support system which supports clinicians in accessing the most appropriate diagnostic test for their patients. Innovations such as the Smart Vetting workflow also reduce workloads for administrative and clinical staff, while improving patient safety and care.
- Streets Heaver's Compucare® PAS/EPR (patient administration system/electronic patient record): This market-leading solution is designed for private patient workflows as well as managing NHS contracts and eReferrals. It supports all clinical activity types from general clinic consultations to diagnostic imaging workflows, as well as other non-imaging diagnostic services. Patient engagement is supported through the Patient Portal.
About AGFA HealthCare
At AGFA HealthCare, we are transforming the delivery of care - supporting healthcare professionals across the globe with secure, effective, and sustainable imaging data management. As a company, we are dedicated to our customers, and we have harnessed a value framework of Mission, Vision, and Customer Delivery Principles into our routine operations. Through these principles, we commit a consistent high-yield code of conduct to our associates - channelling our experience and aspirations to all our stakeholders. Our Empowerer profile supports our focus on creating an exceptional experience through the power of technology and is an integral foundation of our company standards. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com and follow us on LinkedIn.
AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO® is a registered trademark of AGFA HealthCare N.V. All rights reserved. Compucare is a registered trademark of Streets Heaver Computer Systems Ltd. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.
Contact Information
Buse Kayar
buse.kayar@issuerdirect.com
SOURCE: AGFA HealthCare
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Loar Announces Pricing of Upsized Public Offering10.12.2024 23:40:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 10, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar"), announced today the pricing of its upsized public offering of 5,750,000 shares of its common stock, including 1,897,500 shares offered by certain stockholders and 3,852,500 shares offered by Loar at $85.00 per share. The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 862,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 12, 2024, subject to customary closing conditions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any
PHYLA Announces a Series of International Collaborations With the University of Bradford and UPM and a Significant Government-Supported Land Regeneration Project in the Gambia10.12.2024 14:00:00 CET | Press release
LONDON, UK PHYLA and the University of Bradford join forces to develop marketable compounds, cosmetics and superfood products from the pongamia plant PHYLA has entered into a commercial agreement with the University of Bradford to develop marketable bio-compounds for cosmetics and superfood products derived from the pongamia (oil tree) plant which are cultivated in PHYLA's land regeneration projects. The partnership aims to leverage PHYLA's existing IP by applying specific extraction technologies which maximise the yield and value of bio-compounds and other plant-based products. Phyla's Pongamia Pods Phyla's high-density pongamia pod cluster Professor Anant Paradkar, Director of The Centre for Pharmaceutical Engineering Science (CPES) at the University of Bradford, commented: "We are thrilled to collaborate with PHYLA to advance the development of plant-based products. Our Centre has a long-standing commitment to green and sustainable extraction technologies, and this partnership align
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom